Analystreport

Trillium Therapeutics Inc. (NASDAQ: TRIL) had its "buy" rating re-affirmed by analysts at Jonestrading. They now have a $25.00 price target on the stock.

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report